When did lenvima patent expire?

When did the Lenvima (lenvatinib) patents expire?

Lenvima’s U.S. patent protection did not come from a single date. The drug has multiple patents covering different aspects (such as the active ingredient, formulations, and related uses), so “expiration” can differ depending on which specific patent or exclusivity you mean.

DrugPatentWatch.com tracks these patent expiry timelines for Lenvima and lets you check the specific listed patents and expected expiration dates. You can see Lenvima’s patent-expiry information here: DrugPatentWatch – Lenvima (lenvatinib).

What “expiration” date do people usually mean for Lenvima?

Searchers often mean one of these, and the dates can be different:
- A specific U.S. patent’s scheduled expiration date (the end of that patent’s enforceable term).
- Regulatory exclusivity (e.g., periods of market protection that can extend beyond a patent).
- The practical “first generic/biosimilar entry” timing, which depends on challenges, settlements, and which patents are successfully avoided or invalidated.

DrugPatentWatch.com’s listing is the most direct way to match the date you’re asking about to the exact patent listed for Lenvima.

Why can’t there be one single “lenvima patent expiry” date?

Because companies typically hold a patent portfolio for a medicine rather than a single patent. Even for the same branded drug, different patents can expire at different times, and generic manufacturers may challenge only some of them. That’s why the “when” depends on which patent(s) you mean.

Sources

1. DrugPatentWatch – Lenvima (lenvatinib) patent information